Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
New draft guidance could see the agency getting ever stricter.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
